Global Diarrhea Drug

Diarrhea Drug Comprehensive Study by Type (Adult, Children), Application (Family, Hospital), Form (Syringe, Tablets), Dosage (10 mg, 15 mg, 20 mg, 30 mg) Players and Region - Global Market Outlook to 2028

Diarrhea Drug Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Diarrhea is denoted as a condition marked by frequent, loose watery stools. Diarrhea drugs are applicable to treat sudden diarrhea and possess the mechanism of slowing down the movement of the gut. This helps to reduce the number of bowel movements and also makes the stools less watery. According to the WHO, diarrhea is the second leading cause of death, especially in children less than 5 years of age. Prevention of diarrheal disease can be achieved by drinking of safe water coupled with adequate hygiene and sanitation. The major companies are adding more innovative techniques in Asia-Pacific countries as these countries are focused on the fastest-growing verticals for the healthcare sector.This growth is primarily driven by Increasing Prevalence of Diarrhea Diseases .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Pharmaceuticals sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as HPGC (Srilanka), Simcere (China), Hailisheng (China), Sichuan Weiao (China), Shanxi Kangxin (China), Ipsen (France), Evaluate (United Kingdom) and Gamay (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In October 2019, RedHill Biopharma Ltd. strategic collaboration with Cosmo pharmaceuticals N.V. This collaboration will focus on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.
In March 2021, Drug major Lupin on Wednesday said it has launched Nitazoxanide tablets (500 mg), used to treat diarrhea.The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Regulatory Insights:
“According to U.S. Food and Drug Administration approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.”

Market Growth Drivers:
Increasing Prevalence of Diarrhea Diseases and Rising Awareness among Customers

Challenges:
Wrong Labelling Leads to Product Calls

Restraints:
In Availability of Drugs at Remote Regions and Stiff Competition among Major Players

Opportunities:
Upsurge Demand from Asia-Pacific Regions and Government Investments towards Research and Development Fields

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Diarrhea Drug Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Diarrhea Drug Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Diarrhea Drug players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Diarrhea Drug Study Sheds Light on
— The Diarrhea Drug Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Diarrhea Drug industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Diarrhea Drug industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Adult
  • Children
By Application
  • Family
  • Hospital
By Form
  • Syringe
  • Tablets

By Dosage
  • 10 mg
  • 15 mg
  • 20 mg
  • 30 mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Diarrhea Diseases
      • 3.2.2. Rising Awareness among Customers
    • 3.3. Market Challenges
      • 3.3.1. Wrong Labelling Leads to Product Calls
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Diarrhea Drug, by Type, Application, Form, Dosage and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Diarrhea Drug (Value)
      • 5.2.1. Global Diarrhea Drug by: Type (Value)
        • 5.2.1.1. Adult
        • 5.2.1.2. Children
      • 5.2.2. Global Diarrhea Drug by: Application (Value)
        • 5.2.2.1. Family
        • 5.2.2.2. Hospital
      • 5.2.3. Global Diarrhea Drug by: Form (Value)
        • 5.2.3.1. Syringe
        • 5.2.3.2. Tablets
      • 5.2.4. Global Diarrhea Drug by: Dosage (Value)
        • 5.2.4.1. 10 mg
        • 5.2.4.2. 15 mg
        • 5.2.4.3. 20 mg
        • 5.2.4.4. 30 mg
      • 5.2.5. Global Diarrhea Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Diarrhea Drug (Price)
      • 5.3.1. Global Diarrhea Drug by: Type (Price)
  • 6. Diarrhea Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. HPGC (Srilanka)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Simcere (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Hailisheng (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sichuan Weiao (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shanxi Kangxin (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Ipsen (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Evaluate (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Gamay (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Diarrhea Drug Sale, by Type, Application, Form, Dosage and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Diarrhea Drug (Value)
      • 7.2.1. Global Diarrhea Drug by: Type (Value)
        • 7.2.1.1. Adult
        • 7.2.1.2. Children
      • 7.2.2. Global Diarrhea Drug by: Application (Value)
        • 7.2.2.1. Family
        • 7.2.2.2. Hospital
      • 7.2.3. Global Diarrhea Drug by: Form (Value)
        • 7.2.3.1. Syringe
        • 7.2.3.2. Tablets
      • 7.2.4. Global Diarrhea Drug by: Dosage (Value)
        • 7.2.4.1. 10 mg
        • 7.2.4.2. 15 mg
        • 7.2.4.3. 20 mg
        • 7.2.4.4. 30 mg
      • 7.2.5. Global Diarrhea Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Diarrhea Drug (Price)
      • 7.3.1. Global Diarrhea Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diarrhea Drug: by Type(USD Million)
  • Table 2. Diarrhea Drug Adult , by Region USD Million (2017-2022)
  • Table 3. Diarrhea Drug Children , by Region USD Million (2017-2022)
  • Table 4. Diarrhea Drug: by Application(USD Million)
  • Table 5. Diarrhea Drug Family , by Region USD Million (2017-2022)
  • Table 6. Diarrhea Drug Hospital , by Region USD Million (2017-2022)
  • Table 7. Diarrhea Drug: by Form(USD Million)
  • Table 8. Diarrhea Drug Syringe , by Region USD Million (2017-2022)
  • Table 9. Diarrhea Drug Tablets , by Region USD Million (2017-2022)
  • Table 10. Diarrhea Drug: by Dosage(USD Million)
  • Table 11. Diarrhea Drug 10 mg , by Region USD Million (2017-2022)
  • Table 12. Diarrhea Drug 15 mg , by Region USD Million (2017-2022)
  • Table 13. Diarrhea Drug 20 mg , by Region USD Million (2017-2022)
  • Table 14. Diarrhea Drug 30 mg , by Region USD Million (2017-2022)
  • Table 15. South America Diarrhea Drug, by Country USD Million (2017-2022)
  • Table 16. South America Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 17. South America Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 18. South America Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 19. South America Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 20. Brazil Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 21. Brazil Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 22. Brazil Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 23. Brazil Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 24. Argentina Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 25. Argentina Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 26. Argentina Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 27. Argentina Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 28. Rest of South America Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 29. Rest of South America Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 30. Rest of South America Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 31. Rest of South America Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 32. Asia Pacific Diarrhea Drug, by Country USD Million (2017-2022)
  • Table 33. Asia Pacific Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 34. Asia Pacific Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 35. Asia Pacific Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 36. Asia Pacific Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 37. China Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 38. China Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 39. China Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 40. China Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 41. Japan Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 42. Japan Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 43. Japan Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 44. Japan Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 45. India Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 46. India Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 47. India Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 48. India Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 49. South Korea Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 50. South Korea Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 51. South Korea Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 52. South Korea Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 53. Taiwan Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 54. Taiwan Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 55. Taiwan Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 56. Taiwan Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 57. Australia Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 58. Australia Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 59. Australia Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 60. Australia Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 61. Rest of Asia-Pacific Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 65. Europe Diarrhea Drug, by Country USD Million (2017-2022)
  • Table 66. Europe Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 67. Europe Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 68. Europe Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 69. Europe Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 70. Germany Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 71. Germany Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 72. Germany Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 73. Germany Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 74. France Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 75. France Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 76. France Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 77. France Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 78. Italy Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 79. Italy Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 80. Italy Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 81. Italy Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 82. United Kingdom Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 83. United Kingdom Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 84. United Kingdom Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 85. United Kingdom Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 86. Netherlands Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 87. Netherlands Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 88. Netherlands Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 89. Netherlands Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 90. Rest of Europe Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 91. Rest of Europe Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 92. Rest of Europe Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 93. Rest of Europe Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 94. MEA Diarrhea Drug, by Country USD Million (2017-2022)
  • Table 95. MEA Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 96. MEA Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 97. MEA Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 98. MEA Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 99. Middle East Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 100. Middle East Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 101. Middle East Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 102. Middle East Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 103. Africa Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 104. Africa Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 105. Africa Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 106. Africa Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 107. North America Diarrhea Drug, by Country USD Million (2017-2022)
  • Table 108. North America Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 109. North America Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 110. North America Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 111. North America Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 112. United States Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 113. United States Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 114. United States Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 115. United States Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 116. Canada Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 117. Canada Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 118. Canada Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 119. Canada Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 120. Mexico Diarrhea Drug, by Type USD Million (2017-2022)
  • Table 121. Mexico Diarrhea Drug, by Application USD Million (2017-2022)
  • Table 122. Mexico Diarrhea Drug, by Form USD Million (2017-2022)
  • Table 123. Mexico Diarrhea Drug, by Dosage USD Million (2017-2022)
  • Table 124. Diarrhea Drug: by Type(USD/Units)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Diarrhea Drug: by Type(USD Million)
  • Table 134. Diarrhea Drug Adult , by Region USD Million (2023-2028)
  • Table 135. Diarrhea Drug Children , by Region USD Million (2023-2028)
  • Table 136. Diarrhea Drug: by Application(USD Million)
  • Table 137. Diarrhea Drug Family , by Region USD Million (2023-2028)
  • Table 138. Diarrhea Drug Hospital , by Region USD Million (2023-2028)
  • Table 139. Diarrhea Drug: by Form(USD Million)
  • Table 140. Diarrhea Drug Syringe , by Region USD Million (2023-2028)
  • Table 141. Diarrhea Drug Tablets , by Region USD Million (2023-2028)
  • Table 142. Diarrhea Drug: by Dosage(USD Million)
  • Table 143. Diarrhea Drug 10 mg , by Region USD Million (2023-2028)
  • Table 144. Diarrhea Drug 15 mg , by Region USD Million (2023-2028)
  • Table 145. Diarrhea Drug 20 mg , by Region USD Million (2023-2028)
  • Table 146. Diarrhea Drug 30 mg , by Region USD Million (2023-2028)
  • Table 147. South America Diarrhea Drug, by Country USD Million (2023-2028)
  • Table 148. South America Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 149. South America Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 150. South America Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 151. South America Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 152. Brazil Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 153. Brazil Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 154. Brazil Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 155. Brazil Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 156. Argentina Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 157. Argentina Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 158. Argentina Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 159. Argentina Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 160. Rest of South America Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 161. Rest of South America Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 162. Rest of South America Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 163. Rest of South America Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 164. Asia Pacific Diarrhea Drug, by Country USD Million (2023-2028)
  • Table 165. Asia Pacific Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 166. Asia Pacific Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 167. Asia Pacific Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 168. Asia Pacific Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 169. China Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 170. China Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 171. China Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 172. China Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 173. Japan Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 174. Japan Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 175. Japan Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 176. Japan Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 177. India Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 178. India Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 179. India Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 180. India Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 181. South Korea Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 182. South Korea Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 183. South Korea Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 184. South Korea Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 185. Taiwan Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 186. Taiwan Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 187. Taiwan Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 188. Taiwan Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 189. Australia Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 190. Australia Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 191. Australia Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 192. Australia Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 193. Rest of Asia-Pacific Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 194. Rest of Asia-Pacific Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 195. Rest of Asia-Pacific Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 196. Rest of Asia-Pacific Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 197. Europe Diarrhea Drug, by Country USD Million (2023-2028)
  • Table 198. Europe Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 199. Europe Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 200. Europe Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 201. Europe Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 202. Germany Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 203. Germany Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 204. Germany Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 205. Germany Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 206. France Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 207. France Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 208. France Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 209. France Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 210. Italy Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 211. Italy Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 212. Italy Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 213. Italy Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 214. United Kingdom Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 215. United Kingdom Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 216. United Kingdom Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 217. United Kingdom Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 218. Netherlands Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 219. Netherlands Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 220. Netherlands Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 221. Netherlands Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 222. Rest of Europe Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 223. Rest of Europe Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 224. Rest of Europe Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 225. Rest of Europe Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 226. MEA Diarrhea Drug, by Country USD Million (2023-2028)
  • Table 227. MEA Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 228. MEA Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 229. MEA Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 230. MEA Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 231. Middle East Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 232. Middle East Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 233. Middle East Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 234. Middle East Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 235. Africa Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 236. Africa Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 237. Africa Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 238. Africa Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 239. North America Diarrhea Drug, by Country USD Million (2023-2028)
  • Table 240. North America Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 241. North America Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 242. North America Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 243. North America Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 244. United States Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 245. United States Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 246. United States Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 247. United States Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 248. Canada Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 249. Canada Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 250. Canada Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 251. Canada Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 252. Mexico Diarrhea Drug, by Type USD Million (2023-2028)
  • Table 253. Mexico Diarrhea Drug, by Application USD Million (2023-2028)
  • Table 254. Mexico Diarrhea Drug, by Form USD Million (2023-2028)
  • Table 255. Mexico Diarrhea Drug, by Dosage USD Million (2023-2028)
  • Table 256. Diarrhea Drug: by Type(USD/Units)
  • Table 257. Research Programs/Design for This Report
  • Table 258. Key Data Information from Secondary Sources
  • Table 259. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diarrhea Drug: by Type USD Million (2017-2022)
  • Figure 5. Global Diarrhea Drug: by Application USD Million (2017-2022)
  • Figure 6. Global Diarrhea Drug: by Form USD Million (2017-2022)
  • Figure 7. Global Diarrhea Drug: by Dosage USD Million (2017-2022)
  • Figure 8. South America Diarrhea Drug Share (%), by Country
  • Figure 9. Asia Pacific Diarrhea Drug Share (%), by Country
  • Figure 10. Europe Diarrhea Drug Share (%), by Country
  • Figure 11. MEA Diarrhea Drug Share (%), by Country
  • Figure 12. North America Diarrhea Drug Share (%), by Country
  • Figure 13. Global Diarrhea Drug: by Type USD/Units (2017-2022)
  • Figure 14. Global Diarrhea Drug share by Players 2022 (%)
  • Figure 15. Global Diarrhea Drug share by Players (Top 3) 2022(%)
  • Figure 16. Global Diarrhea Drug share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. HPGC (Srilanka) Revenue, Net Income and Gross profit
  • Figure 19. HPGC (Srilanka) Revenue: by Geography 2022
  • Figure 20. Simcere (China) Revenue, Net Income and Gross profit
  • Figure 21. Simcere (China) Revenue: by Geography 2022
  • Figure 22. Hailisheng (China) Revenue, Net Income and Gross profit
  • Figure 23. Hailisheng (China) Revenue: by Geography 2022
  • Figure 24. Sichuan Weiao (China) Revenue, Net Income and Gross profit
  • Figure 25. Sichuan Weiao (China) Revenue: by Geography 2022
  • Figure 26. Shanxi Kangxin (China) Revenue, Net Income and Gross profit
  • Figure 27. Shanxi Kangxin (China) Revenue: by Geography 2022
  • Figure 28. Ipsen (France) Revenue, Net Income and Gross profit
  • Figure 29. Ipsen (France) Revenue: by Geography 2022
  • Figure 30. Evaluate (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Evaluate (United Kingdom) Revenue: by Geography 2022
  • Figure 32. Gamay (United States) Revenue, Net Income and Gross profit
  • Figure 33. Gamay (United States) Revenue: by Geography 2022
  • Figure 34. Global Diarrhea Drug: by Type USD Million (2023-2028)
  • Figure 35. Global Diarrhea Drug: by Application USD Million (2023-2028)
  • Figure 36. Global Diarrhea Drug: by Form USD Million (2023-2028)
  • Figure 37. Global Diarrhea Drug: by Dosage USD Million (2023-2028)
  • Figure 38. South America Diarrhea Drug Share (%), by Country
  • Figure 39. Asia Pacific Diarrhea Drug Share (%), by Country
  • Figure 40. Europe Diarrhea Drug Share (%), by Country
  • Figure 41. MEA Diarrhea Drug Share (%), by Country
  • Figure 42. North America Diarrhea Drug Share (%), by Country
  • Figure 43. Global Diarrhea Drug: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • HPGC (Srilanka)
  • Simcere (China)
  • Hailisheng (China)
  • Sichuan Weiao (China)
  • Shanxi Kangxin (China)
  • Ipsen (France)
  • Evaluate (United Kingdom)
  • Gamay (United States)
Select User Access Type

Key Highlights of Report


Dec 2023 233 Pages 92 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Diarrhea Drug Quantitative research analysis
Global Diarrhea Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Diarrhea Drug Market are HPGC (Srilanka), Simcere (China), Hailisheng (China), Sichuan Weiao (China), Shanxi Kangxin (China), Ipsen (France), Evaluate (United Kingdom) and Gamay (United States) etc.
Family segment in Global market to hold robust market share owing to "Increasing Prevalence of Diarrhea Diseases ".
AMA Research predicts that China Players will contribute to the maximum growth of Global Diarrhea Drug market throughout the forecasted period.

Know More About Global Diarrhea Drug Report?

Have a Query? Click Here

Other Related Reports

Caspase 3 Comprehensive Study by Type (1G3-Cu, BaxM-159, Emricasan, IDN-7314, Others), Application (Liver Cirrhosis, Liver Failure, Pulmonary Fibrosis, Solid Tumor, Others) Players and Region - Globa...
$ 3400
Docetaxel Comprehensive Study by Type (40 mg/ml, 20 mg/ml, 10 mg/ml), Application (Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric Adenocarcinoma Cancer, Head and Neck Cancer), En...
$ 3650
Doxorubicin Comprehensive Study by Type (Lyophilized Powder, Doxorubicin Injection), Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast Cancer, Gastric Cancer, Oth...
$ 3450
Bone Substitutes Comprehensive Study by Type (Bone Grafts {Autograft, Allograft, Xenograft}, Ceramics {Hydroxyapatite, Tricalcium Phosphate (TCP), Calcium Sulphate}, Growth Factors {Demineralized Bon...
$ 3750
Latanoprost Comprehensive Study by Type (Brand Drug, Generic Drug), Application (Open-angle Glaucoma, Close-angle Glaucoma), End Users (Pediatrics, Adults, Geriatrics), Bottle Size (2.5 ml, 5 ml, Oth...
$ 3500
Aspirin Comprehensive Study by Type (99.5% Purity, 99% Purity, Others), Application (Tablets Product, Capsule Product, Others), End-User (Hospitals, Ambulatory Surgical Center (ASC), Others) Players ...
$ 3500